A Look At Novozymes (CPSE:NSIS B) Valuation After Recent Share Price Weakness

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

Novozymes (CPSE:NSIS B) has drawn investor attention after recent share price moves, with the stock down about 5% year to date and about 13% over the past year on a total return basis.

See our latest analysis for Novozymes.

The share price has eased in recent months, with a 90 day share price return of a 1.77% decline and a 1 year total shareholder return down 12.74%, suggesting momentum has been fading despite a 3 year total shareholder return of 11.42%.

If this kind of mixed performance has you looking further afield, it could be a good moment to widen your watchlist and check out 103 top founder-led companies

So with Novozymes showing solid recent revenue and net income growth but the share price still behind its 3 year total return, is this a potential opportunity to gain exposure to biosolutions at a lower valuation, or is the current market price already reflecting expectations for future growth?

Most Popular Narrative: 19.7% Undervalued

The most followed narrative currently points to a fair value of DKK471.06 per share for Novozymes, compared with the last close at DKK378.20. This suggests a sizable upside gap based on that framework.

Strategic build out of commercial and technical presence in high growth emerging markets, combined with a robust innovation pipeline and cross selling synergies from acquisitions such as Feed Enzyme Alliance, should sustain above market volume growth, support the 6% to 9% long term organic growth ambition and enhance earnings resilience.

Read the complete narrative.

Want to see what is baked into that fair value? The narrative leans on sustained revenue expansion, rising profitability and a premium earnings multiple that assumes continued momentum. The precise mix of growth, margins and valuation expectations is where things get interesting.

Result: Fair Value of DKK471.06 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on continued volume growth in key segments and smooth emerging market expansion, and setbacks in either could quickly challenge the undervalued thesis.

Find out about the key risks to this Novozymes narrative.

Another View: Rich Multiples Temper The Story

That 19.7% gap to the DKK471.06 fair value hinges on strong earnings expectations. Yet on a simple P/E basis, Novozymes appears expensive at 39.5x compared with a fair ratio of 29.4x and a European Chemicals average of 17.7x. This points to less of a bargain and more valuation risk if sentiment cools.